Alzheimer Disease Clinical Trials in Toms River, New Jersey

5 studies are recruiting for alzheimer disease in Toms River, New Jersey right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies now recruiting

1. Study of LHP588 in Subjects With P. Gingivalis-Positive Alzheimer's Disease

   This study is to test LHP588 in persons who have mild to moderate Alzheimer's disease (AD) who have shown progressive mental decline in the last year and who have P. gingivalis (Pg) infection. P. gingivalis infection has been linked to the development of dementia. LHP588 is designed to target the P…

   Stage

   Phase 2

   Ages

   55 to 80

   Site

   CenExel Research - Toms River, Toms River, New Jersey

   Locations

   38 in total

   Run by

   Lighthouse Pharmaceuticals, Inc.

   See if you can join NCT06847321 on ClinicalTrials.gov

2. Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986368, for the Treatment of Agitation in Participants With Alzheimer's Disease

   This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alzheimer's Disease.

   Stage

   Phase 2

   Ages

   55 to 90

   Site

   Local Institution - 0081, Toms River, New Jersey

   Locations

   78 in total

   Run by

   Celgene

   See if you can join NCT06808984 on ClinicalTrials.gov

3. A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

   This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled, flexible-dose study evaluating the efficacy, safety, and tolerability of ITI-1284 compared with placebo in the treatment of psychosis in patients with AD.

   Stage

   Phase 2

   Ages

   55 and older

   Site

   Bio Behavioral Health, Toms River, New Jersey

   Locations

   67 in total

   Run by

   Intra-Cellular Therapies, Inc.

   See if you can join NCT06540833 on ClinicalTrials.gov

4. A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)

   The purpose of this study is to evaluate the safety and efficacy of KarXT in adult participants with mild to severe Alzheimer's Disease (AD) with moderate to severe psychosis related to AD.

   Stage

   Phase 3

   Ages

   55 to 90

   Site

   Advanced Memory Research Institute - CenExel - PPDS, Toms River, New Jersey

   Locations

   293 in total

   Run by

   Karuna Therapeutics, Inc., a Bristol Myers Squibb company

   See if you can join NCT06585787 on ClinicalTrials.gov

5. A First-In-Human Study of LY3954068 in Participants With Early Symptomatic Alzheimer's Disease

   The main purpose of this study is to evaluate the safety of LY3954068 in participants with early symptomatic Alzheimer's Disease (AD). The study will also investigate how much LY3954068 gets into the bloodstream and will test the effects of LY3954068 on markers of AD. The study will be comprised of…

   Stage

   Phase 1

   Ages

   50 to 85

   Site

   CenExel AMRI, Toms River, New Jersey

   Locations

   10 in total

   Run by

   Eli Lilly and Company

   See if you can join NCT06297590 on ClinicalTrials.gov